Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now stepping into the spotlight as weight loss drugs. A recent umbrella review draws attention to safety concerns regarding the use of this GLP medication, alongside a mix of potential benefits.
The review selected studies that looked beyond non-cardiometabolic outcomes such as blood sugar, weight, and heart and kidney health. The search narrowed to 60 meta-analyses covering 1,751 randomized clinical trials with over 3.5 million participants, and found a strong association between GLP-1 medications and gastrointestinal side effects, including nausea, diarrhea, and vomiting.
The researchers also found that drugs might actually protect against certain serious infections and be beneficial for bone, brain and lung health. However, further research is required to draw solid conclusions regarding these benefits. The findings are published in JAMA Network Open.
Beyond diabetes and weight loss
GLP-1 RAs mimic a natural hormone in the body, which is released from the gut after eating, to regulate blood sugar and appetite. These agonists activate the same GLP-1 receptors in the stomach and gut that help slow down stomach emptying, make people feel full sooner and for longer, reducing overall food intake.
At the same time, they signal the pancreas to release insulin when blood sugar levels rise. Together, these effects help improve glucose control while also supporting weight management.
There have been numerous studies looking into the metabolic and cardiovascular benefits or risks associated with the drugs. Still, their potential role in a much broader spectrum of health outcomes remains less known.
With the growing use of GLP-1 RAs, clinicians and patients alike need a clearer picture of the potential risks and benefits, particularly beyond their established role.
In this study, the team searched several major medical databases to identify all relevant studies involving randomized clinical trials (RCTs), the gold standard of medical research, in which GLP-1 drugs were compared with a placebo or other medications. They only focused on noncardiometabolic outcomes.
The most consistent finding was that these medications are strongly linked to gastrointestinal side effects. However, these also showed some unexpected benefits beyond their role in diabetes.
Evidence suggests the drugs may lower the risk of serious infections and support lung health by reducing airway inflammation and oxidative stress. At the same time, the weight loss they trigger can improve conditions such as sleep apnea.
There were also indications of possible brain benefits, including protection against dementia through improved blood flow and reduced buildup of harmful proteins. The drugs could also strengthen bones and lower the risk of fractures, though this remains less certain.
The findings from this study support careful monitoring for gastrointestinal side effects in patients using GLP-1 RAs. Before these drugs are seriously considered for treatment or prevention of infections, respiratory conditions or dementia, the researchers urge caution, noting that the information identified so far is exploratory and will require stronger evidence from future studies.